BioCatalystFeed / Readout calendar / FDA decisions / Drugs / Disease areas / Companies / Months

Biotech catalysts in 2025-07

196 industry Phase 2/3 trial readout(s) and 42 FDA decision event(s). Readouts include completed (ACTUAL) and still-estimated primary completion dates in this month, any status.

← 2025-06 | 2025-08 →

FDA decision events

DateEventStatusCompanyDrugSource
2025-07-01FDA approvalapprovedELI LILLY CO LLYKISUNLAApproved 2025-07-01: KISUNLA (BLA761248 SUPPL4)
2025-07-02FDA approvalapprovedDIZALZEGFROVYApproved 2025-07-02: ZEGFROVY (NDA219839 ORIG1)
2025-07-02FDA approvalapprovedRENGENERON PHARMACEUTICALS, INC.LYNOZYFICApproved 2025-07-02: LYNOZYFIC (BLA761400 ORIG1)
2025-07-03FDA approvalapprovedKALVISTAEKTERLYApproved 2025-07-03: EKTERLY (NDA219301 ORIG1)
2025-07-03FDA approvalapprovedAVYXA HOLDINGSGOBARDENApproved 2025-07-03: GOBARDEN (NDA219014 ORIG1)
2025-07-03FDA approvalapprovedRECORDATI RAREISTURISAApproved 2025-07-03: ISTURISA (NDA212801 SUPPL4)
2025-07-07Complete response lettercomplete responseUltragenyx Pharmaceutical Inc. RARECRL 2025-07-07: Ultragenyx Pharmaceutical Inc. BL 125845
2025-07-09FDA AdComheldAdCom 2025-07-09: Pediatric Advisory Committee (PAC)
2025-07-09Complete response lettercomplete responseCapricor, Inc. CAPRyour product, deramiocelCRL 2025-07-09: Capricor, Inc. BL 125842 (your product, deramiocel)
2025-07-10FDA approvalapprovedTAKEDA PHARMS USA TAKMOTEGRITYApproved 2025-07-10: MOTEGRITY (NDA210166 SUPPL4)
2025-07-10FDA approvalapprovedPFIZER INC PFEELREXFIOApproved 2025-07-10: ELREXFIO (BLA761345 SUPPL3)
2025-07-11FDA approvalapprovedBAYER HLTHCAREKERENDIAApproved 2025-07-11: KERENDIA (NDA215341 SUPPL9)
2025-07-15FDA approvalapprovedBIOCON BIOLOGICS INCKIRSTYApproved 2025-07-15: KIRSTY (BLA761188 ORIG1)
2025-07-16FDA approvalapprovedFRESENIUS KABI USAGLYCOPYRROLATEApproved 2025-07-16: GLYCOPYRROLATE (NDA214919 SUPPL2)
2025-07-16FDA approvalapprovedSAGENTFAMOTIDINEApproved 2025-07-16: FAMOTIDINE (NDA219935 ORIG1)
2025-07-16FDA approvalapprovedHIKMAROBINULApproved 2025-07-16: ROBINUL (NDA017558 SUPPL68)
2025-07-16FDA approvalapprovedEXELA PHARMAGLYRX-PFApproved 2025-07-16: GLYRX-PF (NDA210997 SUPPL8)
2025-07-17FDA AdComheldGlaxoSmithKline LLCAdCom 2025-07-17: Oncologic Drugs Advisory Committee - BLA 761440
2025-07-18FDA AdComheldOtsuka Pharmaceutical Company, Ltd.AdCom 2025-07-18: Psychopharmacologic Drugs Advisory Committee - sNDA 205422/S-012
2025-07-21Complete response lettercomplete responseReplimune, Inc. REPLvusolimogene oderparepvecCRL 2025-07-21: Replimune, Inc. BL 125827 (vusolimogene oderparepvec)
2025-07-23FDA approvalapprovedROSEMONT PHARMSVOSTALLYApproved 2025-07-23: VOSTALLY (NDA219757 ORIG1)
2025-07-23FDA approvalapprovedAMGEN INC AMGNOTEZLAApproved 2025-07-23: OTEZLA (NDA205437 SUPPL14)
2025-07-23FDA approvalapprovedALTATHERA PHARMS LLCSOTALOL HYDROCHLORIDEApproved 2025-07-23: SOTALOL HYDROCHLORIDE (NDA022306 SUPPL8)
2025-07-23FDA approvalapprovedLEO PHARMA ASANZUPGOApproved 2025-07-23: ANZUPGO (NDA219155 ORIG1)
2025-07-24FDA approvalapprovedAKARX INCDOPTELET SPRINKLEApproved 2025-07-24: DOPTELET SPRINKLE (NDA219696 ORIG1)
2025-07-24FDA approvalapprovedAKARX INCDOPTELETApproved 2025-07-24: DOPTELET (NDA210238 SUPPL10)
2025-07-24FDA approvalapprovedMERCK SHARP DOHME MRKKEYTRUDAApproved 2025-07-24: KEYTRUDA (BLA125514 SUPPL178)
2025-07-24FDA approvalapprovedBRILLIAN PHARMASDAMLOApproved 2025-07-24: SDAMLO (NDA219531 ORIG1)
2025-07-25FDA approvalapprovedASCENDIS PHARMA ENCOCRINOLOGY DIV A/S ASNDSKYTROFAApproved 2025-07-25: SKYTROFA (BLA761177 SUPPL8)
2025-07-28Complete response lettercomplete responseHeritage Pharmaceuticals Inc. d/b/a/ Avet Pharmaceuticals Inc.CRL 2025-07-28: Heritage Pharmaceuticals Inc. d/b/a/ Avet Pharmaceuticals Inc. NDA 205508
2025-07-28FDA approvalapprovedAPELLIS PHARMSEMPAVELIApproved 2025-07-28: EMPAVELI (NDA215014 SUPPL11)
2025-07-28FDA approvalapprovedJANSSEN THERAPSIRTUROApproved 2025-07-28: SIRTURO (NDA204384 SUPPL20)
2025-07-28FDA approvalapprovedPTC THERAPSEPHIENCEApproved 2025-07-28: SEPHIENCE (NDA219666 ORIG1)
2025-07-29FDA approvalapprovedCARWIN PHARM ASSOCVYSCOXAApproved 2025-07-29: VYSCOXA (NDA211759 ORIG1)
2025-07-30Complete response lettercomplete responseTeva Pharmaceuticals, Inc. TEVATVB-009CRL 2025-07-30: Teva Pharmaceuticals, Inc. BLA 761385 (TVB-009)
2025-07-30Complete response lettercomplete responseRegeneron Pharmaceuticals, Inc. REGNCRL 2025-07-30: Regeneron Pharmaceuticals, Inc. BLA 761303
2025-07-30Complete response lettercomplete responseConjupro Biotherapeutics Inc.CRL 2025-07-30: Conjupro Biotherapeutics Inc. NDA 218923
2025-07-30FDA approvalapprovedROSEMONT PHARMSATMEKSIApproved 2025-07-30: ATMEKSI (NDA219843 ORIG1)
2025-07-30FDA approvalapprovedGILEAD SCIENCES INC GILDBIKTARVYApproved 2025-07-30: BIKTARVY (NDA210251 SUPPL23)
2025-07-31FDA approvalapprovedNOVO NORDISK INC NVOALHEMOApproved 2025-07-31: ALHEMO (BLA761428 ORIG1)
2025-07-31FDA approvalapprovedLENZ THERAP LENZVIZZApproved 2025-07-31: VIZZ (NDA218585 ORIG1)
2025-07-31FDA approvalapprovedNOVARTIS NVSLEQVIOApproved 2025-07-31: LEQVIO (NDA214012 SUPPL16)

Trial readouts

ReadoutPhaseSponsorTrialConditionsStatusEnrollment
2025-07 est.P2EMSNCT02873468 Efficacy and Safety of Three Doses of Florence Oral Suspension in Adults With Eosinophilic EsophagitisEosinophilic Esophagitisunknown116
2025-07 est.P2Matrix Biomed, Inc.NCT03480971 Treatment of Radiation and Cisplatin Induced Toxicities with TempolMucositis; Nephrotoxicity; Ototoxicityrecruiting120
2025-07 est.P2ImaginAb, Inc.NCT05013099 Study of Zirconium Zr 89 Crefmirlimab Berdoxam PET/CT in Subjects With Advanced or Metastatic MalignanciesMelanoma; Merkel Cell Carcinoma, Unspecified; Renal Cell Carcinoma; Non Small Cell Lung Cancerunknown70
2025-07 est.P2Adaptive Phage Therapeutics, Inc.NCT05269134 Bacteriophage Therapy in Patients With Prosthetic Joint Infections (PJI)Prosthetic Joint Infectionwithdrawn
2025-07 est.P3Vanda Pharmaceuticals VNDANCT05361707 Evaluating the Effects of Tasimelteon in Individuals With Autism Spectrum Disorder (ASD) and Sleep DisturbancesAutism Spectrum Disorder; Sleep Disorder; Neurological Disorder; Sleep Disturbanceunknown100
2025-07 est.P1/P2Smart Immune SASNCT05768035 Safety and Efficacy of SMART101 in Adult Patients With Hematological Malignancies After Haploidentical HSCT With Post-transplant CyclophosphamideHematological Malignanciesunknown40
2025-07 est.P2/P3Gelscom SASNCT05969392 Evaluation of Efficacy and Safety of Intradiscal Gelified Ethanol in Refractory Cervical Discogenic PainPain, Cervical; Discogenic Painnot yet recruiting60
2025-07 est.P2/P3SPA Società Prodotti Antibiotici S.p.A.NCT06263517 Clinical Trial to Assess Efficacy, Tolerability of Rising Doses of Clodronate in Painful Knee Osteoarthritis PatientsOsteoarthritis of Kneeunknown296
2025-07 est.P2Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. SBFMNCT06412471 A Phase II Study of SSGJ-707 Combination Therapy in Advanced NSCLC PatientsFirst-line Advanced NSCLC Patientsunknown235
2025-07 est.P1/P2Krystal Biotech, Inc. KRYSNCT06724900 A Study Assessing KB304 for the Treatment of Wrinkles in WomenWrinkles in Decolletage; Pigmentation; Décolleté Wrinklesactive not recruiting19
2025-07 est.P2Praxis Precision Medicines PRAXNCT06908356 An Open Label Trial to Evaluate the Efficacy and Safety of PRAX-628 in Adults With Focal Onset or Tonic-Clonic SeizuresFocal Onset Seizure; Primary Generalized Epilepsyrecruiting50
2025-07-01P1/P2PharmaMarNCT02611024 Pharmacokinetic Study of Lurbinectedin in Combination With Irinotecan in Patients With Selected Solid TumorsAdvanced Solid Tumors; Glioblastoma; Soft Tissue Sarcoma (Excluding GIST); Endometrial Carcinoma; Epcompleted316
2025-07-01P1/P2Incyte Biosciences Japan GK INCYNCT04661007 To Assess the Safety and Tolerability of Tafasitamab Alone or in Combination With Other Drugs in Japanese Participants With Non-Hodgkins Lymphoma (NHL)Non Hodgkins Lymphoma; Diffuse Large B-cell Lymphomaactive not recruiting72
2025-07-01P3Takeda TAKNCT04779307 A Study of Vedolizumab in Children and Teenagers With Moderate to Severe Ulcerative Colitis (UC)Colitis, Ulcerativecompleted121
2025-07-01P3HK inno.N CorporationNCT04840550 Study to Evaluate the Safety, Efficacy of Tegoprazan for the Prevention of PUD in Patients on Treatment With NSAIDsPreventive Peptic Ulcercompleted392
2025-07-01P3Telix Pharmaceuticals (Innovations) Pty Ltd TLXNCT04876651 The Present Study Aims to Compare Patients Who Receive the Investigational Product (177Lu-DOTA-rosopatamab) Plus Standard of Care, in Comparison to Standard of Metastatic Prostate Cancerterminated16
2025-07-01P3Jiangsu HengRui Medicine Co., Ltd.NCT06254742 A Trial of HHPG-19K Injection and Auto-HHPG-19K Injection in Prevention of Chemotherapy-related Moderate to Severe Neutropenia of Patients With Nonmyeloid MaligPatients With Nonmyeloid Malignancies Receiving Antineoplastic Therapy Based on Chemotherapy Regimenwithdrawn
2025-07-01 est.P1/P2Empower Research IncNCT06471959 Psychedelic-assisted Group Program for First RespondersPsilocybin; Psychotherapy, Groupunknown32
2025-07-01P2/P3CanSino Biologics Inc.NCT06708286 A Clinical Trials of Adsorbed Cell-free DPT Vaccine (Five-component)Diphtheria; Tetanus; Pertussiscompleted1820
2025-07-02P3Daiichi SankyoNCT04622319 A Study of Trastuzumab Deruxtecan (T-DXd) Versus Trastuzumab Emtansine (T-DM1) in High-risk HER2-positive Participants With Residual Invasive Breast Cancer FollHER2-Positive Primary Breast Cancer; Residual Invasive Breast Canceractive not recruiting1600
2025-07-02P1/P2Sanofi SNYNCT04717375 Study of SAR444881 Administered Alone and in Combination With Other Therapeutics in Participants With Advanced Solid TumorsCancer; Neoplasmterminated125
2025-07-02P3Chia Tai Tianqing Pharmaceutical Group Co., Ltd.NCT05365178 To Evaluate the Efficacy and Safety of TQB3616 in Combination With Fulvestrant Versus Placebo in Combination With Fulvestrant in Previously Untreated Hormone-reHR-positive, HER2-negative Breast Neoplasmsactive not recruiting432
2025-07-02P2Amgen AMGNNCT05669014 A Phase 2 Proof of Concept Study to Evaluate the Efficacy and Safety of Daxdilimab in Participants With Dermatomyositis (DM) or Anti-synthetase Inflammatory MyoIdiopathic Inflammatory Myositiscompleted12
2025-07-02P2argenx ARGXNCT05810948 A Study to Assess Effectiveness and Safety of Efgartigimod in Chinese Patients With Lupus Nephritis (ZL-1103-013)Lupus Nephritiscompleted73
2025-07-02P2Elios Therapeutics, LLCNCT06175221 Autologous TLPO Vaccine BasketTumor, Solid; Tumor Metastasis; Cancer; Tumorterminated63
2025-07-03P2BayerNCT00694850 Impact of Multiple Doses of BAY63-2521 on Safety, Tolerability, Pharmacokinetics and Pharmacodynamics in Patients With Interstitial Lung Disease (ILD) AssociateHypertension, Pulmonarycompleted22
2025-07-03P2Janssen Research & Development, LLCNCT04640623 A Study of TAR-200 in Combination With Cetrelimab, TAR-200 Alone, or Cetrelimab Alone in Participants With Non-Muscle Invasive Bladder Cancer (NMIBC) UnresponsiUrinary Bladder Neoplasmsactive not recruiting220
2025-07-03P3Aurinia Pharmaceuticals Inc. AUPHNCT05288855 Voclosporin in Adolescent and Pediatric Subjects With Lupus NephritisAdolescent Lupus Nephritis; Pediatric Lupus Nephritisterminated9
2025-07-03P2Partner Therapeutics, Inc.NCT05588609 Study Evaluating Zenocutuzumab in Patients With or Without Molecularly Defined CancersNSCLC Harboring NRG1 Fusion; Metastatic Castration-resistant Prostate Cancerterminated13
2025-07-03P2Pfizer PFENCT06712836 A Phase 2b Study to Examine the Safety and Efficacy of Once-Weekly MET097 in Adults With Obesity or OverweightObesity; Overweight or Obesitycompleted239
2025-07-04P3Gilead Sciences GILDNCT04527991 Study of Sacituzumab Govitecan Versus Physician's Choice of Treatment in Participants With Urothelial Cancer That Cannot Be Removed or Has SpreadLocally Advanced or Metastatic Unresectable Urothelial Cancercompleted711
2025-07-04P3Hoffmann-La RocheNCT04958265 A Study Evaluating the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of Crovalimab in Pediatric Participants With Atypical Hemolytic Uremic Syndrome (Atypical Hemolytic Uremic Syndromeactive not recruiting41
2025-07-04P3Aurinia Pharmaceuticals Inc. AUPHNCT05962788 Long-Term Voclosporin Treatment in Adolescent and Pediatric Subjects With Lupus NephritisAdolescent Lupus Nephritis; Pediatric Lupus Nephritisterminated4
2025-07-04P2Beijing Suncadia Pharmaceuticals Co., LtdNCT06109831 Evaluate the Efficacy and Safety of SHR-1918 in Patients With HyperlipidemicHyperlipidemiccompleted335
2025-07-05 est.P1/P2S.Biomedics Co., Ltd.NCT04818203 A Study on the Anti-Wrinkle Efficacy Assessment and Safety Evaluation of the Cluster of Autologous Dermal Fibroblast on Bilateral Crow's FeetCrow's Feetrecruiting80
2025-07-05P1/P2Bristol-Myers Squibb BMYNCT05337137 A Study of Nivolumab and Relatlimab in Combination With Bevacizumab in Advanced Liver CancerCarcinoma, Hepatocellularcompleted82
2025-07-06P1/P2CellCentric Ltd.NCT03568656 Study to Evaluate CCS1477 in Advanced TumoursMetastatic Castration-Resistant Prostate Cancer; Metastatic Breast Cancer; Non-small Cell Lung Cancecompleted219
2025-07-07P1/P2Jasper Therapeutics, Inc. JSPRNCT02963064 JSP191 Antibody Targeting Conditioning in SCID PatientsSCIDterminated23
2025-07-07P3Incyte Corporation INCYNCT03656536 A Study to Evaluate the Efficacy and Safety of Pemigatinib Versus Chemotherapy in Unresectable or Metastatic CholangiocarcinomaUnresectable Cholangiocarcinoma; Metastatic Cholangiocarcinomaterminated167
2025-07-07P2/P3Vertex Pharmaceuticals Incorporated VERXNCT03745287 A Safety and Efficacy Study Evaluating CTX001 in Subjects With Severe Sickle Cell DiseaseSickle Cell Disease; Hematological Diseases; Hemoglobinopathiescompleted63
2025-07-07P2Jiangsu HengRui Medicine Co., Ltd.NCT04680988 A Study of SHR-1210± SHR-1020 Versus Chemotherapy in Patients With Recurrent or Metastatic Cervical CancerRecurrent or Metastatic Cervical Cancercompleted194
2025-07-07 est.P2Biogen BIIBNCT05764122 A Study to Evaluate the Efficacy and Safety of BIIB131 for Participants With Ischemic Stroke Between 4.5 and 24 Hours After Last Known WellIschemic Strokewithdrawn
2025-07-07P389bio, Inc.NCT05852431 To Evaluate the Efficacy and Safety of Pegozafermin in Subjects With Severe HypertriglyceridemiaSevere Hypertriglyceridemiacompleted369
2025-07-07P3Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.NCT05899179 Clinical Study of Recombinant Mycobacterium Tuberculosis Fusion Protein for 65-year-olds and AboveLatent Tuberculosis Infectioncompleted780
2025-07-07P2Carmot Therapeutics, Inc.NCT06062069 A Study of CT-868 in Type 1 Diabetes MellitusOverweight; Obese; Type 1 Diabetes Mellituscompleted111
2025-07-07P2Upstream Bio Inc. UPBNCT06164704 A Study to Investigate the Efficacy and Safety of Verekitug (UPB-101) in Participants With Chronic Rhinosinusitis With Nasal PolypsChronic Rhinosinusitis With Nasal Polypscompleted81
2025-07-07P3AbbVie ABBVNCT06241313 Study of Oral Atogepant Tablets to Assess Safety and Efficacy in Adult Participants With MigraineMigrainecompleted2158
2025-07-07P3Fujian Shengdi Pharmaceutical Co., Ltd.NCT06396429 To Compare the Efficacy and Safety of HRS9531 and Placebo in Subjects With Overweight or ObeseOverweight or Obesitycompleted567
2025-07-08P3Biogen BIIBNCT02283853 Phase 3 Efficacy and Safety Study of BG00012 in Pediatric Participants With Relapsing-Remitting Multiple Sclerosis (RRMS)Relapsing-Remitting Multiple Sclerosiscompleted156
2025-07-08P3Regeneron Pharmaceuticals REGNNCT05070858 A Study to Test How Safe Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Alone Are and How Well They Work in Adult Patients With Generalized MyastheGeneralized Myasthenia Gravisactive not recruiting288
2025-07-08P2SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, GermanyNCT05348356 Nirogacestat in Ovarian Granulosa Cell TumorsOvarian Granulosa-Stromal Tumor; Ovarian Granulosa Cell Tumor; Ovarian Cancercompleted53
2025-07-08P3Hoffmann-La RocheNCT05987423 Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Satralizumab in Participants With Thyroid Eye DiseaseThyroid Eye Disease; TEDcompleted131
2025-07-08P1/P2ModernaTX, Inc.NCT05995275 A Study to Investigate The Safety, Tolerability, And Immune Response of a Range of Doses of mRNA-1769 Compared With Placebo in Healthy Participants From ≥18 YeaSmallpox; Mpoxcompleted351
2025-07-08P1/P2Hoffmann-La RocheNCT06055075 A Study Evaluating Safety, Tolerability, and Clinical Activity of Forimtamig-Based Treatment Combinations in Participants With Relapsed or Refractory Multiple MRelapsed or Refractory Multiple Myelomaterminated21
2025-07-08P2Nanjing Chia-tai Tianqing PharmaceuticalNCT06764303 A Study of NTQ5082 Capsules in the Treatment of Paroxysmal Nocturnal Hemoglobinuria PatientsParoxysmal Nocturnal Hemoglobinuriaactive not recruiting24
2025-07-08P3Yangtze River Pharmaceutical Group Jiangsu Zilong Pharmaceutical Co. LtdNCT06949852 Evaluation of Safety and Efficacy of Nalbuphine Versus Morphine for Postoperative AnalgesiaPostoperative Analgesiacompleted289
2025-07-09P2Arcus Biosciences, Inc. RCUSNCT04262856 Study to Evaluate Monotherapy and Combination Immunotherapies in Participants With PD-L1 Positive Non-small Cell Lung CancerNon Small Cell Lung Cancer; Nonsquamous Non Small Cell Lung Cancer; Squamous Non Small Cell Lung Cancompleted151
2025-07-09P1/P2SyntaraNCT04676529 Study to Evaluate Safety, Pharmacokinetic and Pharmacodynamic Dose Escalation and Expansion Study of PXS-5505 in Patients With Primary, Post-polycythemia Vera oMyelofibrosis; Primary Myelofibrosis (PMF); Post- Essential Thrombocythemia Myelofibrosis; Post Polycompleted43
2025-07-09P2BioAtla, Inc. BCABNCT04681131 CAB-AXL-ADC Safety and Efficacy Study in Adults With NSCLCNon-Small-Cell Lung Cancercompleted85
2025-07-09P2Regend TherapeuticsNCT05638776 Treatment of Chronic Obstructive Pulmonary Disease (COPD) With Diffusion Capacity Defect by REGEND001 Cell TherapyChronic Obstructive Pulmonary Diseasecompleted58
2025-07-09P3Alexion Pharmaceuticals, Inc.NCT06079281 Phase 3 Study of ALXN1850 Versus Placebo in Adolescent and Adult Participants With HPP Who Have Not Previously Been Treated With Asfotase AlfaHypophosphatasiaactive not recruiting124
2025-07-09P2/P3Takeda TAKNCT06741683 A Study of Dengue Tetravalent Vaccine (TDV) in Healthy Participants in JapanDengue Fevercompleted187
2025-07-10P2Nanjing Legend Biotech Co.NCT03758417 A Study of LCAR-B38M CAR-T Cells, a Chimeric Antigen Receptor T-cell (CAR-T) Therapy Directed Against B-cell Maturation Antigen (BCMA) in Chinese Participants WMultiple Myelomaterminated123
2025-07-10P2Leap Therapeutics, Inc.NCT05480306 Phase 2 Study of DKN-01 in Colorectal CancerColorectal Cancer; Colorectal Adenocarcinoma; Colo-rectal Cancer; Colorectal Cancer Metastaticcompleted188
2025-07-10P2Albireo, an Ipsen CompanyNCT05642468 Safety and Tolerability of A3907 in Primary Sclerosing CholangitisPrimary Sclerosing Cholangitisterminated18
2025-07-10P2/P3RemeGen Co., Ltd.NCT05980481 A Study of RC48-ADC Combination Therapies as First-line Treatment in Advanced Metastatic Gastric CancerGastric Canceractive not recruiting201
2025-07-10P3Dong-A ST Co., Ltd.NCT06151210 Clinical Trial to Evaluate the Efficacy and Safety of DA-5219 in Patients With Acute or Chronic GastritisGastritis Acute; Gastritis Chroniccompleted467
2025-07-10P2Pfizer PFENCT06465368 A Study to Learn About the Study Medicine PF-07220060 Together With Letrozole Compared to Letrozole Alone in Women Post MenopauseBreast Cancercompleted121
2025-07-10P2Vyne Therapeutics Inc.NCT06493578 A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of VYN201 Gel in Subjects With Non-segmental Vitiligo.Non-segmental Vitiligoterminated205
2025-07-10P3Ahn-Gook Pharmaceuticals Co.,LtdNCT06717360 A Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of AG2304T and AG2304RHypercholesterolemiacompleted158
2025-07-10 est.P2Cisen Pharmaceutical CO., LTD.NCT06771063 A Study of the Efficacy and Safety of WXSH0102 in Treating VCC PatientsVaginitisrecruiting108
2025-07-10P2Haisco Pharmaceutical Group Co., Ltd.NCT07140328 Evaluation of the Safety and Efficacy of HSK39004 Dry Powder Inhaler and HSK39004 Inhalation Suspension in Chinese Patients With Chronic Obstructive Pulmonary DChronic Obstructive Lung Disease (COLD)recruiting50
2025-07-11P3Loxo Oncology, Inc.NCT05023980 A Study of Pirtobrutinib (LOXO-305) Versus Bendamustine Plus Rituximab (BR) in Untreated Patients With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic LympChronic Lymphocytic Leukemia; Small Lymphocytic Lymphomaactive not recruiting282
2025-07-11P3InflaRx GmbH IFRXNCT05964413 Phase III Trial to Investigate Efficacy and Safety of Vilobelimab in Ulcerative Pyoderma GangrenosumPyoderma Gangrenosumterminated54
2025-07-14P3Bristol-Myers Squibb BMYNCT05328908 A Study of Nivolumab-relatlimab Fixed-dose Combination Versus Regorafenib or TAS-102 in Participants With Later-lines of Metastatic Colorectal CancerColorectal Neoplasmsterminated769
2025-07-14P2AstraZeneca AZNNCT05809934 A Study to Evaluate AZD2693 in Participants Who Are Carriers of the PNPLA3 148M Risk Allele With Non-cirrhotic Non-alcoholic Steatohepatitis With FibrosisNonalcoholic Steatohepatitiscompleted220
2025-07-14P2Janssen Research & Development, LLCNCT06083753 Study to Evaluate the Safety and Efficacy of PIPE-307 in Subjects With Relapsing-Remitting Multiple SclerosisRelapsing Remitting Multiple Sclerosiscompleted182
2025-07-14P2Knoa Pharma LLCNCT06545929 Study of Sunobinop on Craving in Alcohol Use DisorderAlcohol Use Disordercompleted40
2025-07-14P1/P2Shandong Suncadia Medicine Co., Ltd.NCT06621316 A Study of Safety and Tolerability of Multiple Doses of HRS-7535 in Obese SubjectsOverweight or Obesitycompleted74
2025-07-15P2AstraZeneca AZNNCT05737940 A Study of AZD3427 in Participants With Heart Failure and Pulmonary Hypertension Group 2Pulmonary Hypertension (World Health Organization Group 2); Heart Failurecompleted260
2025-07-15 est.P2Jiangsu Healthy Life Innovation Medical Technology Co., LtdNCT06353360 TTField in Combination With Temozolomide and Tislelizumab in The Treatment of Newly Diagnosed Glioblastoma.Glioblastoma Multiformeunknown30
2025-07-15P2Shandong Suncadia Medicine Co., Ltd.NCT06415214 Efficacy and Safety of HRS-7535 Tablets in Adults With Diabetic Kidney Disease in Type 2 DiabetesDiabetic Kidney Disease, Type 2 Diabetescompleted281
2025-07-15P3Nanjing Zenshine PharmaceuticalsNCT06669351 Study to Assess the Safety and Efficacy of ZX-7101A in Children Aged 5-11 Years With InfluenzaRespiratory Viral Infectionterminated98
2025-07-15P2Neurocentria, Inc.NCT06673368 A Phase 2 Randomized Double-Blind, Parallel, Adaptive-Design, Clinical Trial to Evaluate the Safety and Efficacy of NRCT-101SR With NRCT-202XR Compared to NRCT-ADHDterminated2
2025-07-15P1/P2BioNTech SE BNTXNCT06683352 A Study to Learn About Flu and COVID-19 Vaccine Responses in Healthy PeopleInfluenza,Human; COVID-19completed1353
2025-07-15P2Taisho Pharmaceutical Co., Ltd.NCT06745518 A Phase 2 Study of TS-172 in Hyperphosphatemia Patients on Hemodialysis With Phosphate BindersHyperphosphatemia Patients on Hemodialysiscompleted62
2025-07-16P2Sunshine Lake Pharma Co., Ltd. SBFMNCT05060822 Phase ll Study of HEC585 in Patients With IPFIdiopathic Pulmonary Fibrosisactive not recruiting270
2025-07-16P3Amgen AMGNNCT05198934 Sotorasib and Panitumumab Versus Investigator's Choice for Participants With Kirsten Rat Sarcoma (KRAS) p.G12C MutationColorectal Cancer (CRC)completed160
2025-07-16P3Genentech, Inc.NCT05306340 A Study Evaluating the Efficacy and Safety of Giredestrant Plus Everolimus Compared With the Physician's Choice of Endocrine Therapy Plus Everolimus in ParticipEstrogen Receptor (ER)-Positive, HER2-negative, Locally Advanced or Metastatic Breast Canceractive not recruiting373
2025-07-16P3Cassiopea SpANCT05914805 A Study to Evaluate the Efficacy and Safety of Clascoterone Solution in Treatment of Male Pattern Hair Loss (SCALP2)Alopecia, Androgeneticcompleted762
2025-07-16P2Brii Biosciences LimitedNCT05970289 Investigate the Efficacy and Safety of BRII-835 (VIR-2218) and PEG-IFNα Combination Therapy in Chronic HBV PatientsChronic Hepatitis B Virus Infectioncompleted86
2025-07-16P2Pelage Pharmaceuticals, Inc.NCT06393452 Safety, Pharmacokinetics and Efficacy of PP405 in Adults With AGAAndrogenetic Alopeciacompleted78
2025-07-17P3Hoffmann-La RocheNCT03599245 This is an Extension Study of the Roche P-trials to Investigate Safety and Effectiveness of Ocrelizumab in Participants With Multiple Sclerosis (MS)Multiple Sclerosiscompleted1055
2025-07-17P1/P2Sangamo Therapeutics SGMOQNCT03653247 A Study to Assess the Safety, Tolerability, and Efficacy of BIVV003 for Autologous Hematopoietic Stem Cell Transplantation in Patients With Severe Sickle Cell DSickle Cell Diseasecompleted7
2025-07-17P1/P2Hutchison Medipharma LimitedNCT05173142 A Phase Ib/II Clinical Study Evaluating HMPL-453 Tartrate as Monotherapy and in Combination With Chemotherapy or Toripalimab in Advanced Solid TumorsSolid Tumorcompleted190
2025-07-17P1/P2UCB Biopharma SRLNCT05277571 A Single-ascending Dose (Part A) and Repeat-dose (Part B) Study to Investigate the Safety, Pharmacokinetics and Efficacy (Part B Only) of UCB1381 in Healthy StuAtopic Dermatitiscompleted109
2025-07-17P3Regeneron Pharmaceuticals REGNNCT05394116 A Study to Assess Safety, Tolerability and Efficacy of Garetosmab Versus Placebo Administered Intravenously (IV) in Adult Participants With Fibrodysplasia OssifFibrodysplasia Ossificans Progressivaactive not recruiting63
2025-07-17P3Priovant Therapeutics, Inc.NCT05437263 A Study to Investigate the Efficacy and Safety of Brepocitinib in Adults With DermatomyositisDermatomyositiscompleted241
2025-07-17 est.P2CNBG-Virogin Biotech (Shanghai) Ltd.NCT06126510 Clinical Study of VG161 in the Treatment of Advanced Bone and Soft Tissue SarcomaSarcomarecruiting40
2025-07-17P1/P2Alnylam Pharmaceuticals ALNYNCT06423352 A Study to Evaluate Zilebesiran in Japanese Patients With Mild to Moderate HypertensionMild to Moderate Hypertensioncompleted36
2025-07-17P2Chia Tai Tianqing Pharmaceutical Group Co., Ltd.NCT06990776 A Clinical Trial to Evaluate the Efficacy and Safety of TQA3605 Tablets in Treatment-naive Chronic HBV-infected SubjectsChronic Hepatitis Bwithdrawn
2025-07-18P2AbbVie ABBVNCT02782663 A Study to Evaluate the Long-Term Efficacy, Safety, and Tolerability of Repeated Administration of Upadacitinib (ABT-494) in Participants With Crohn's DiseaseCrohn's Disease (CD)completed107
2025-07-18P2Moleac Pte Ltd.NCT05289947 MLC1501 Study Assessing Efficacy in Post STrOke Subjects With mOtor DeficitsStroke; Stroke, Ischemic; Strokes Thrombotic; Stroke Sequelae; Stroke, Cardiovascular; Stroke, Embolcompleted303
2025-07-18P3Tetra Discovery PartnersNCT05358886 A Study of BPN14770 in Male Adults (Aged 18 to 45) With Fragile X SyndromeFragile X Syndromecompleted171
2025-07-18P1/P2BeOne Medicines ONCNCT05471843 Study of Sonrotoclax (BGB-11417) Monotherapy in Participants With Relapsed or Refractory Mantle Cell LymphomaMantle Cell Lymphoma; Refractory Mantle Cell Lymphoma (MCL); Relapsed Mantle Cell Lymphomaactive not recruiting125
2025-07-18P3Pentixapharm AGNCT06125028 [68Ga]Ga-PentixaFor-PET Imaging for Staging of Marginal Zone LymphomaMarginal Zone Lymphomaterminated8
2025-07-18 est.P3Yuhan CorporationNCT06625957 Clinical Trial to Evaluate the Safety and Efficacy of NTCB02-1 in Patients Who Require Parenteral NutritionParenteral Nutritionrecruiting60
2025-07-19P2Dicot ABNCT06703840 Phase 2a Trial to Investigate the Efficacy of LIB-01 in Treatment of Erectile DysfunctionErectile Dysfunctioncompleted156
2025-07-20P2Guangdong Raynovent Biotech Co., LtdNCT06254274 A Study of RAY1225 in Participants With Type 2 DiabetesT2DM (Type 2 Diabetes Mellitus)completed210
2025-07-20P3Novo Nordisk A/S NVONCT06588504 Research Study in Japan to Compare Dasiglucagon With Glucagon in Treating Very Low Levels of Blood Sugar in Asian Adults With Type 1 Diabetes and Testing of DasDiabetes Mellitus, Type 1completed38
2025-07-21P3Pfizer PFENCT05634811 Safety Study of a Vaccine to Help Protect Against Lyme Disease in Healthy ChildrenLyme Diseasecompleted3547
2025-07-21P2Sichuan Baili Pharmaceutical Co., Ltd.NCT06445400 A Study of BL-M07D1, BL-M07D1+Pertuzumab and BL-M07D1+Pertuzumab+Docetaxel in Patients With Unresectable Locally Advanced or Metastatic HER2-positive Breast CanHER2-positive Breast Canceractive not recruiting83
2025-07-21P3Shanghai Haiyan Pharmaceutical Technology Co., Ltd.NCT06975514 Safety and Efficacy Study of YZJ-1139 Tablets in Insomnia DisorderInsomnia Disordercompleted61
2025-07-22P3Rare Thyroid Therapeutics International ABNCT05579327 Withdrawal of Tiratricol Treatment in Males With Monocarboxylate Transporter 8 Deficiency (MCT8 Deficiency)Monocarboxylate Transporter 8 Deficiency; Allan-Herndon-Dudley Syndromecompleted20
2025-07-22P1/P2Revelation Biosciences, Inc REVBNCT06863467 Evaluation of the Safety and Tolerability of Gemini in Subjects With Stage 3-4 Chronic Kidney Disease.Renal Insufficiency, Chronic; Chronic Kidney Disease stage3; Chronic Kidney Disease stage4completed40
2025-07-23P2GlaxoSmithKlineNCT05999799 A Dose Finding Study to Investigate the Safety and Effectiveness of GSK1070806 in Adult Participants With Moderate to Severe Atopic DermatitisDermatitis, Atopicterminated161
2025-07-23P3Alexion Pharmaceuticals, Inc.NCT06079372 Phase 3 Study of ALXN1850 in Pediatric Participants With HPP Previously Treated With Asfotase AlfaHypophosphatasiaactive not recruiting43
2025-07-23P3RDC Clinical Pty LtdNCT06104917 Effect of Maolactin on Gastrointestinal Tract (GIT) HealthGastrointestinal Dysfunctioncompleted91
2025-07-23P3Sanofi SNYNCT06130566 A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab Monotherapy Compared With Placebo in Participants Aged 12 Years and Older With Moderate-Dermatitis Atopiccompleted601
2025-07-23P3Bionorica SENCT06211049 Efficacy of Vitex Agnus-castus BNO 1095 (20 mg) in Women With Primary DysmenorrheaPrimary Dysmenorrheacompleted335
2025-07-24P2Novartis Pharmaceuticals NVSNCT04675931 To Evaluate Efficacy, Safety, Tolerability and PK of Intravenous Cipargamin in Participants With Severe Plasmodium Falciparum MalariaSevere Malariacompleted254
2025-07-24P2Novo Nordisk A/S NVONCT05405114 Research Study Investigating How Well NDec Works in People With Sickle Cell DiseaseSickle Cell Diseasecompleted96
2025-07-24P2Biotheus Inc.NCT05864105 PM8002 in Combination With Chemotherapy as First Line Therapy in Hepatocellular CarcinomaHepatocellular Carcinomacompleted35
2025-07-24P2ITB-Med LLCNCT06025110 A Study of TCD601 (Siplizumab) in New Onset Type 1 Diabetes PatientsDiabetes Mellitus, Type 1terminated9
2025-07-24P3AstraZeneca AZNNCT06042049 A Study to Assess Safety, Pharmacokinetics Anti-Drug Antibody and Anti-RSV Antibody After 2 Doses of NirsevimabRespiratory Syncytial Virus Infectionscompleted33
2025-07-24P3Hoffmann-La RocheNCT06106828 A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Satralizumab in Participants With Thyroid Eye DiseaseThyroid Eye Diseasecompleted127
2025-07-24P2DICE Therapeutics, Inc., a wholly owned subsidiary of Eli Lilly and CompanyNCT06602219 A Study of LY4100511 (DC-853) in Adult Participants With Moderate-to-Severe Plaque PsoriasisPlaque Psoriasiscompleted222
2025-07-24P2Lynk Pharmaceuticals Co., LtdNCT07071610 A Study to Evaluate the Efficacy and Safety of LNK01004 Ointment in Adults With Atopic DermatitisAtopic Dermatitiscompleted75
2025-07-25P3Amgen AMGNNCT03872401 Effect of Evolocumab in Patients at High Cardiovascular Risk Without Prior Myocardial Infarction or StrokeCoronary Heart Disease (CHD)completed12301
2025-07-25P3Eli Lilly and Company LLYNCT05869903 A Study of Orforglipron (LY3502970) in Adult Participants With Obesity or Overweight With Weight-Related ComorbiditiesObesity; Overweight; Overweight or Obesityactive not recruiting3127
2025-07-25P2Immunovant Sciences GmbH IMVTNCT05907668 A Proof-of-Concept Study to Assess Batoclimab in Participants With Graves' DiseaseGraves Diseasecompleted32
2025-07-25P2Neurocrine Biosciences NBIXNCT06267846 A Study to Evaluate the Efficacy and Safety of NBI-1070770 in Adults With Major Depressive DisorderMajor Depressive Disordercompleted73
2025-07-27P3National Vaccine and Serum Institute, ChinaNCT05916326 Phase III Clinical Trial to Evaluate the Human Norovirus Bivalent (GⅠ.1/GⅡ.4)Vaccine,Recombinant (Hansenula Polymorpha)Norovirus Infections; Norwalk Gastroenteritiscompleted8000
2025-07-27P2TransThera Sciences (Nanjing), Inc.NCT06057571 Study of TT-00420 (Tinengotinib) in Subjects With Cholangiocarcinoma Who Failed or Relapsed to Chemotherapy and FGFR InhibitorCholangiocarcinoma Metastaticactive not recruiting50
2025-07-27P3Zhuhai Trinomab Pharmaceutical Co., Ltd.NCT06710925 A Sudy to Evaluate the Efficacy and Safety of TNM001 in High-risk InfantsRespiratory Syncytial Virus Infectionscompleted315
2025-07-28P2BrainX CorporationNCT03413384 To Assess the Efficacy and Safety of Ceftriaxone in Patients With Mild to Moderate Parkinson's Disease DementiaParkinson's Disease Dementiacompleted100
2025-07-28P3AstraZeneca AZNNCT04053634 Efficacy and Safety of Benralizumab in Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD) With a History of Frequent ExacerbationsChronic Obstructive Pulmonary Diseasecompleted689
2025-07-28P2/P3ModernaTX, Inc.NCT05127434 A Study to Evaluate the Safety and Efficacy of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ≥60 Years of AgeRespiratory Syncytial Viruscompleted36814
2025-07-28P1/P2Takeda TAKNCT05220098 First-in-Human Study of TAK-280 in Participants With Solid TumorsUnresectable Locally Advanced or Metastatic Cancerterminated69
2025-07-28P2Takeda TAKNCT05526391 A Study of TAK-341 in Treatment of Multiple System AtrophyMultiple System Atrophycompleted158
2025-07-28P3Pathalys PharmaNCT05832931 Parathyroid Hormone (PTH) Attenuation Trial in Hemodialysis-1Secondary Hyperparathyroidism; End-stage Kidney Disease (ESKD)completed362
2025-07-28P3Merck Sharp & Dohme LLC MRKNCT05952856 A Study of Enlicitide Decanoate (MK-0616 Oral PCSK9 Inhibitor) in Adults With Hypercholesterolemia (MK-0616-013) CORALreef LipidsHypercholesterolemia; Familial Hypercholesterolemiacompleted2912
2025-07-28P1/P2Windtree TherapeuticsNCT05975021 A Safety and Efficacy Trial of Istaroxime for Cardiogenic Shock Stage CCardiogenic Shockactive not recruiting20
2025-07-28P2CinPhloro Pharma, LLCNCT06153420 Study of the Research Medicine CIN-103 in Adults With Irritable Bowel Syndrome With Predominant Diarrhea (IBS-D).Irritable Bowel Syndrome With Diarrheaterminated421
2025-07-28P2Dianthus Therapeutics DNTHNCT06282159 A Phase 2 Study to Evaluate DNTH103 in Adults With Generalized Myasthenia Gravis (MAGIC)Myasthenia Gravis, Generalizedactive not recruiting65
2025-07-28P3Fujian Shengdi Pharmaceutical Co., Ltd.NCT06554184 HR20013 for Nausea and Vomiting Associated With Moderate Emetic Risk Anticancer AgentsNausea and Vomiting Associated With Moderate Emetic Risk Anticancer Agentscompleted706
2025-07-28P3Senju Pharmaceutical Science & Technology (Beijing) Co., Ltd.NCT06717152 Efficacy and Safety of SJP-0132 Eye Drops in Chinese Patients With Dry Eye DiseaseDry Eyecompleted427
2025-07-28P2AstraZeneca AZNNCT06750276 A Study to Evaluate the Safety, Tolerability, PK, and PD Effects of AZD2389 in Participants With Liver Fibrosis and Compensated Cirrhosis.Liver Fibrosis; Hepatic Cirrhosiscompleted40
2025-07-29P2Merck Sharp & Dohme LLC MRKNCT04740307 Safety and Efficacy of Coformulated Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib (E7080/MK-7902) in Advanced Hepatocellular Carcinoma (MKAdvanced Hepatocellular Carcinomacompleted116
2025-07-29P3Bristol-Myers Squibb BMYNCT04810078 A Study of Subcutaneous Nivolumab Versus Intravenous Nivolumab in Participants With Previously Treated Clear Cell Renal Cell Carcinoma That is Advanced or Has SClear Cell Renal Cell Carcinomaactive not recruiting681
2025-07-29P1/P2Otsuka Pharmaceutical Development & Commercialization, Inc.NCT05781399 First-in-Human, Multiple Part Clinical Study of JNT-517 in Healthy Participants and in Participants With PhenylketonuriaPhenylketonuriacompleted163
2025-07-29P3Boehringer IngelheimNCT06214741 A Study to Test Whether Survodutide (BI 456906) Helps Chinese People Living With Overweight or Obesity to Lose WeightObesity; Overweightcompleted307
2025-07-29P2GlaxoSmithKlineNCT06447506 Long-Term Study (AtDvance) to Evaluate GSK1070806 in Atopic Dermatitis.Dermatitis, Atopicterminated79
2025-07-29 est.P2Empros Pharma ABNCT06993428 A Trial With EMP16 in Preparation for Late Phase StudiesOverweight or Obese; Obesity and Overweightnot yet recruiting39
2025-07-29P2Eli Lilly and Company LLYNCT07030868 A Study of LY3549492 in Adults With Obesity or Overweight With Type 2 DiabetesObesity; Overweight; Type 2 Diabetesterminated1
2025-07-30P1/P2VBI Vaccines Inc.NCT03382977 Study to Evaluate Safety, Tolerability, and Optimal Dose of Candidate GBM Vaccine VBI-1901 in Recurrent GBM SubjectsGlioblastoma Multiformeterminated70
2025-07-30P2Takeda TAKNCT03635073 A Study of Soticlestat in Adults and Children With Rare EpilepsiesEpilepsy; Dravet Syndrome (DS); Lennox-Gastaut Syndrome (LGS)terminated156
2025-07-30 est.P3LIB Therapeutics LLCNCT04798430 Long-term Efficacy and Safety of OLE LIB003 in HoFH, HeFH, and High-risk CVD Patients Requiring Further LDL-C ReductionCardiovascular Disease With Mention of Arteriosclerosis; Elevated Cholesterol; Familial Hypercholestunknown2000
2025-07-30 est.P3Incepta Pharmaceuticals LtdNCT05056558 Efficacy and Safety of Baricitinib in Patients With Moderate and Severe COVID-19Covid19withdrawn
2025-07-30P2TC BiopharmNCT05358808 ACHIEVE - Efficacy and Effectiveness of Adoptive Cellular tHerapy wIth Ex-Vivo Expanded Allogeneic γδ T-lymphocytes (TCB008) for Patients With Refractory or RelAcute Myeloid Leukemia; Myelodysplastic Syndromesterminated16
2025-07-30P1/P2Cellbion Co., Ltd.NCT05547061 A Phase 1/2 Clinical Trial to Evaluate the Safety, Tolerability, Dosimetry, and Anti-tumor Activity of Ga-68-NGUL / Lu-177-DGUL in Patients With Metastatic CastProstate Cancer; mCRPCcompleted91
2025-07-30 est.P1/P2Beijing InnoCare Pharma Tech Co., Ltd.NCT05719701 Evaluate the Safety, Tolerability, and Efficacy of ICP-490 in Patients With Relapsed and/or Refractory Multiple MyelomaRelapsed and/or Refractory Multiple Myelomaunknown80
2025-07-30 est.P3Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.NCT05755048 FS-1502 Versus T-DM1 for HER2-Positive Unresectable Locally Advanced or Metastatic Breast CancerBreast Cancerunknown314
2025-07-30 est.P3Suzhou Puhe Pharmaceutical Technology Co., LTDNCT05767892 YK-029A as First-Line Treatment Versus Platinum-Based Chemotherapy for Non-Small Cell Lung Cancer (NSCLC) With EGFR Exon 20 Insertion MutationsAdvanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)not yet recruiting350
2025-07-30 est.P3Luye Pharma Group Ltd.NCT05853354 Comparative Efficacy, Safety, PK, and Immunogenicity StudyOsteoporosis, Postmenopausalactive not recruiting392
2025-07-30 est.P3NLS PharmaceuticsNCT05914194 A Eight-Week Study of NLS-2 (Mazindol Extended Release) in Participants With Narcolepsy Type 1Narcolepsy Type 1; Narcolepsy With Cataplexyunknown48
2025-07-30 est.P1/P2Beijing Tide Pharmaceutical Co., LtdNCT05970016 A Phase I/II Clinical Study in Patients with Advanced Solid Tumor.Patients with Advanced Solid Tumorsrecruiting56
2025-07-30P2Merck Sharp & Dohme LLC MRKNCT06161116 Efficacy and Safety of MK-6194 in Adult Participants With Systemic Lupus Erythematosus (MK-6194-006)Systemic Lupus Erythematosusterminated149
2025-07-30P3Bio-Thera SolutionsNCT06280196 A Study to Evaluate PK, Efficacy, and Safety of BAT3306 Plus Chemo and Compare With Keytruda®(EU/US) in Participants With IV nqNSCLCCarcinoma, Non-Small-Cell Lungterminated162
2025-07-30 est.P2MindRank AI LtdNCT06606483 A Study to Evaluate the Efficacy and Safety of MDR-001 in Subjects Who Are Obesity or OverweightObesity; Overweight and Obesityunknown300
2025-07-30P2SpinogenixNCT06833281 Extension Study of Participants From SPG302-ALZ-101Alzheimer's Diseaseterminated12
2025-07-30P2Jiangsu Nhwa Pharmaceutical Co., Ltd.NCT06842992 A Phase II Study to Evaluate NH102 for DepressionMajor Depressive Disorder (MDD)completed243
2025-07-30P2CAGE Bio Inc.NCT06923228 A Study to Assess Efficacy and Safety of CGB-500, 1% Tofacitinib Versus an Active Comparator for Atopic DermatitisAtopic Dermatitis (AD)completed3
2025-07-30P3JW PharmaceuticalNCT06955104 Clinical Trial to Evaluate the Efficacy and Safety of Co-administration of JW0108+C2407 in Patients With DyslipidemiaDyslipidemiacompleted145
2025-07-31P1/P2Vyriad, Inc.NCT03647163 Ph I/II Trial of Systemic VSV-IFNβ-NIS in Combination With Checkpoint Inhibitor Therapy in Patients With Select Solid TumorsSolid Tumor; Non Small Cell Lung Cancer; Neuroendocrine Carcinoma; Renal Cell Carcinoma (RCC)active not recruiting33
2025-07-31P1/P2Heartseed Inc.NCT04945018 A Study of iPS Cell-derived Cardiomyocyte Spheroids (HS-001) in Patients With Heart Failure (LAPiS Study)Heart Failure; Ischemic Heart Diseasecompleted10
2025-07-31P2/P3InnoPharmax Inc.NCT05065957 Study of Combination Therapy of D07001-Softgel Capsules and Xeloda/TS-1 in Subjects With Advanced Biliary Tract CancerBiliary Tract Cancerterminated19
2025-07-31P3Tanabe Pharma CorporationNCT05198557 A Study of MT-0551 in Patients With Systemic SclerosisSystemic Sclerosisactive not recruiting80
2025-07-31 est.P2Epitopoietic Research CorporationNCT05366062 ERC1671 to Treat Malignant Gliomas When Given in Combination With GM-CSF, Cyclophosphamide, Bevacizumab and PembrolizumabGlioma, Malignantunknown28
2025-07-31 est.P3Sinocelltech Ltd.NCT05480293 This Study Will Compare the Efficacy and Safety of SCT510A Administered by Intravitreal Injection (IVT) With Ranibizumab in Patients With wAMDWet Age-related Macular Degenerationunknown446
2025-07-31 est.P2Hrain Biotechnology Co., Ltd.NCT05594797 Human BCMA Targeted T Cells Injection(BCMA CAR-T)for Subjects With R/R MMMultiple Myelomarecruiting100
2025-07-31P2QBiotics Group LimitedNCT05608876 A Clinical Study to Investigate the Efficacy of Tigilanol Tiglate Directly in Head and Neck CancerHead and Neck Canceractive not recruiting15
2025-07-31P3Amgen AMGNNCT05633355 A Study to Assess the Safety, Tolerability, and Efficacy of Rocatinlimab in Adolescent Participants With Moderate-to-severe Atopic Dermatitis (AD)Atopic Dermatitiscompleted187
2025-07-31P2InventisBio Co., LtdNCT05665699 Phase II Study to Evaluate Efficacy and Safety of D-0120 in Combination With Allopurinol in Subjects With GoutGoutcompleted80
2025-07-31 est.P3Shanghai JMT-Bio Inc.NCT05838066 Efficacy and Safety of KN026 in Combination With HB1801 in the First-line Treatment of Subjects With HER2-positive Recurrent or Metastatic Breast Cancer.First-line Treatment of HER2-positive Recurrent or Metastatic Breast Cancerrecruiting880
2025-07-31P3Luye Pharma Group Ltd.NCT05970510 A Study to Evaluate Efficacy and Safety of Toludesvenlafaxine Hydrochloride Sustained-release Tablets in Generalized Anxiety Disorder.Generalized Anxiety Disordercompleted555
2025-07-31P3AbbVie ABBVNCT06137287 A Study to Assess Adverse Events and Change of Masseter Muscle Prominence Using BOTOX Injections in Adult ParticipantsMasseter Muscle Prominencecompleted259
2025-07-31 est.P1/P2CytosinLab Therapeutics Co., Ltd.NCT06224387 CTS2190 Phase I /II Clinical Study in PatientsSolid Tumors; Pancreatic Cancer; Non-small Cell Lung Cancer; Triple-negative Breast Cancerunknown224
2025-07-31P1/P2Jiangsu Alphamab Biopharmaceuticals Co., LtdNCT06226766 JSKN033 in Patients With Advanced or Metastatic Solid Malignant TumorsAdvanced Solid Tumorterminated11
2025-07-31 est.P2SHINKEI Therapeutics, IncNCT06253923 Study to Assess the Safety of Amantadine Hydrochloride (HCl) Intravenous (IV) Solution (MR-301) in Patients With Severe Traumatic Brain Injury (TBI).Traumatic Brain Injuryactive not recruiting45
2025-07-31P1/P2Jasper Therapeutics, Inc. JSPRNCT06353971 A Dose Escalation Trial of Safety, Pharmacokinetic/Pharmacodynamic and Preliminary Clinical Activity of Briquilimab in Adult Patients With Chronic Inducible UrtChronic Inducible Urticariaterminated27
2025-07-31 est.P2Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.NCT06413615 A Study of FDA022-BB05 in Advanced/Metastatic Solid TumorsAdvanced Solid Tumorunknown150
2025-07-31P2Vertanical GmbHNCT06475001 Dose-Response Characterization of VER-01 in the Treatment of Patients With Chronic Non-specific Low Back PainChronic Non-specific Low Back Paincompleted652
2025-07-31 est.P3Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.NCT06569420 Study Of Comparing SAF-189s With Crizotinib In First Line ALK-Positive Advanced and Metastatic NSCLCNon-Small Cell Lung Cancer; ALK-positive; SAF-189sactive not recruiting275
2025-07-31P3Chengdu Suncadia Medicine Co., Ltd.NCT06593938 A Study to Evaluate the Efficacy and Safety of Oral HRS-5965 in Adult Paroxysmal Nocturnal Hemoglobinuria (PNH) Patients Who Are Naive to Complement Inhibitor TParoxysmal Nocturnal Hemoglobinuriacompleted76
2025-07-31P2AkesoNCT06700499 A Study to Evaluate the Efficacy and Safety of AK120 in Subjects With Moderate to Severe Atopic DermatitisAtopic Dermatitiscompleted450

← 2025-06 | 2025-08 →

Readout = ClinicalTrials.gov primary completion date (sponsor-reported; est. dates often slip; top-line results usually follow weeks to months later). FDA events: PDUFA dates are extracted from company 8-K filings (SEC EDGAR) and are company-disclosed and UNVERIFIED - read the filing; AdCom meetings come from Federal Register notices; approvals from Drugs@FDA (openFDA); complete response letters from openFDA (published with a lag). Tickers are matched by name with a confidence score. Generated 2026-11-18T17:57:33Z. Same data: bcf readouts search, bcf fda-decisions search, MCP readout_calendar / fda_decisions. Not investment advice.